Spyre Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | $57.2M | $16.8M |
| Jun 2017 | — | $62.6M | $26.9M |
| Sep 2017 | — | $55.5M | $13.2M |
| Dec 2017 | — | $50.3M | $12.8M |
| Mar 2018 | — | $43.9M | $10.8M |
| Jun 2018 | — | $73.4M | $20.6M |
| Sep 2018 | — | $63.7M | $14.5M |
| Dec 2018 | — | $67.4M | $22.5M |
| Mar 2019 | — | $116.3M | $85.6M |
| Jun 2019 | — | $99.6M | $25.4M |
| Sep 2019 | — | $79.8M | $24.5M |
| Dec 2019 | — | $60.1M | $19.3M |
| Mar 2020 | — | $42.8M | $12.6M |
| Jun 2020 | — | $152.3M | $65.7M |
| Sep 2020 | — | $136.3M | $54.2M |
| Dec 2020 | — | $139.8M | $90.1M |
| Mar 2021 | — | $123.8M | $80.2M |
| Jun 2021 | — | $119.0M | $34.8M |
| Sep 2021 | — | $102.1M | $24.7M |
| Dec 2021 | — | $83.9M | $15.1M |
| Mar 2022 | — | $61.7M | $14.6M |
| Jun 2022 | — | $84.2M | $37.5M |
| Sep 2022 | — | $67.6M | $39.0M |
| Dec 2022 | — | $50.3M | $34.9M |
| Mar 2023 | — | $33.7M | $35.2M |
| Jun 2023 | — | $-207.4M | $235.4M |
| Sep 2023 | — | $-245.4M | $90.6M |
| Dec 2023 | — | $184.0M | $188.9M |
| Mar 2024 | — | $152.3M | $227.6M |
| Jun 2024 | — | $374.4M | $45.1M |
| Sep 2024 | — | $327.4M | $71.6M |
| Dec 2024 | — | $517.8M | $89.4M |
| Mar 2025 | — | $482.6M | $48.5M |
| Jun 2025 | — | $455.8M | $81.7M |
| Sep 2025 | — | $455.1M | $64.9M |
| Dec 2025 | — | $715.2M | $85.7M |
| Mar 2026 | — | $670.8M | $97.2M |
| Jun 2026 | — | $1.10B | $162.0M |